Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Diversion Concerns on the Rise

Kurt Ullman  |  Issue: September 2012  |  September 5, 2012

“Being about a six-hour drive from the Canadian border, we do have patients who get medications from there, primarily because of the lower costs,” says Dr. Daikh. “Although I really don’t have evidence, I think someone physically going to Canada and buying from a licensed pharmacy is more likely to be purchasing from a reliable source.”

However, he does have “a lot of discomfort” when patients tell him they are getting their medications over the Internet or by mail.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA recommends that physicians suggest to their patients that they buy only from pharmacies that are located in the U.S. and are licensed by the state board of pharmacy where the pharmacy is operating. The pharmacy should require a prescription from a physician or other appropriately licensed practitioner before sending the medications. Finally, it should provide contact information that allows the consumer to talk to a pharmacist if they have problems or questions. Additional information about buying prescription drugs over the Internet can be found online at www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/Buying MedicinesOvertheInternet/default.htm.


Kurt Ullman is a freelance writer based in Indiana.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Department of Health and Human Services. Report on prescription drug importation. Published December 2004. Available at archive.hhs.gov/importtaskforce/Report1220.pdf. Accessed July 6, 2012.
  2. Drug Enforcement Administration. “Don’t Be Scammed By A Drug Abuser.” Published December 1999. Available at www.deadiversion.usdoj.gov/pubs/brochures/drugabuser.htm. Accessed May 14, 2012.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Drug UpdatesLegislation & AdvocacyProfessional Topics Tagged with:drugLegislationMedicareMedicationpharmaceuticalrheumatologistSafety

Related Articles

    2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News

    January 1, 2015

    Plus, hydrocodone combination products and brodalumab

    U.S. Lets More Healthcare Workers Prescribe Opioid Addiction Treatment

    January 24, 2018

    WASHINGTON (Reuters)—The U.S. Drug Enforcement Administration said on Tuesday it had changed a regulation to allow more healthcare professionals to prescribe a medication used to treat opioid addiction, opening up access in rural America where there are few doctors.1 Prior to 2000, only physicians could treat those with opioid addiction and had to register with…

    DEA Proposes Cutting Production of Come Opioids

    August 7, 2017

    (Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year. The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences